SSG
GALT icon

Summit Securities Group’s Galectin Therapeutics GALT Stock Holding History

Summit Securities Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-212
Closed -$2K – 550
2013
Q3 		$2K Buy
+212
New +$1.43K ﹤0.01% 341

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Summit Securities Group's GALT Position: Q4 2013 in Review

Summit Securities Group sold out of Galectin Therapeutics (GALT) in Q4 2013, closing a stake of 212 shares — an estimated $2K sold.

Summit Securities Group first reported a position in GALT in Q3 2013 and held it in 1 quarter. The position peaked at $2K in Q3 2013. 33 funds tracked by Wall St. Rank hold GALT as of Q4 2013.

  • Summit Securities Group reported no remaining Galectin Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Summit Securities Group sold 212 Galectin Therapeutics shares in Q4 2013, an estimated $2K.
  • Summit Securities Group first reported a position in Galectin Therapeutics in Q3 2013 and held it in 1 quarter.
  • Summit Securities Group's Galectin Therapeutics position peaked at $2K in Q3 2013.
  • 33 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2013.

Based on Summit Securities Group's 13F filing for Q4 2013, filed 13 Feb 2014.